{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/neuropathic-pain-drug-treatment/prescribing-information/amitriptyline/","result":{"pageContext":{"chapter":{"id":"a91a8f28-db46-58e8-9df7-f30be0f00f2b","slug":"amitriptyline","fullItemName":"Amitriptyline","depth":2,"htmlHeader":"<!-- begin field a4020bd1-e873-4faa-a61b-891e0f61db22 --><h2>Amitriptyline</h2><!-- end field a4020bd1-e873-4faa-a61b-891e0f61db22 -->","summary":"","htmlStringContent":"<!-- begin item 820ce43f-0c36-4731-9198-973080842e7f --><!-- end item 820ce43f-0c36-4731-9198-973080842e7f -->","topic":{"id":"b1f9c908-6cb6-5afd-a737-0a621c6232d0","topicId":"35e3d915-8243-4418-a7dd-6590d8ca5c85","topicName":"Neuropathic pain - drug treatment","slug":"neuropathic-pain-drug-treatment","lastRevised":"Last revised in December 2020","chapters":[{"id":"0c243e96-3697-5ee3-98c7-9ffecf07f2af","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"94d784c6-0537-5187-a548-a95e6ad2f899","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"855f03f8-54cb-5675-a6b8-aeb8064288d7","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"f0b9b63a-bd52-51b6-8eda-cb26c9f551a0","slug":"changes","fullItemName":"Changes"},{"id":"2e3e3fff-20af-56ab-b8f8-a9ee4f14f833","slug":"update","fullItemName":"Update"}]},{"id":"80218328-d006-5b34-a01a-0ef4dbeaf7d5","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"22989c5e-df85-5aba-bd66-8c44723e59d7","slug":"goals","fullItemName":"Goals"},{"id":"722de221-9258-5985-8a02-c088cf258a12","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"bf3b0c22-2d82-5464-bf76-bc066dae256f","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c6576f2f-fd04-5900-a5e1-517233523e2c","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"dd2de31a-79d5-5c20-9132-c99c41c12822","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"148cc621-37d8-5264-a358-c380fcfb4223","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"eddf36b3-7bc8-53c9-9c59-fa36b809f229","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"025ef443-81b5-565d-8240-d76615c27e55","slug":"definition","fullItemName":"Definition"},{"id":"3704349e-d3ae-5a8b-ba94-9da5282ed77f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e18339e8-95d0-582f-ad51-0614dae8f855","slug":"complications","fullItemName":"Complications"},{"id":"9b552f08-01aa-583d-900b-9cbdc90fe28d","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"21d7485a-b855-5ba4-82bc-ca3154184325","fullItemName":"Management","slug":"management","subChapters":[{"id":"bad22859-57ae-5c1c-a944-c3d9fef6d160","slug":"neuropathic-pain-drug-treatment","fullItemName":"Scenario: Neuropathic pain - drug treatment"}]},{"id":"0d8cb386-e038-5d6f-83af-81664da82cca","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a91a8f28-db46-58e8-9df7-f30be0f00f2b","slug":"amitriptyline","fullItemName":"Amitriptyline"},{"id":"382b9603-7b46-57d1-9b07-fa743886796e","slug":"pregabalin","fullItemName":"Pregabalin"},{"id":"498f1249-e619-5b41-b42b-1a914239d269","slug":"gabapentin","fullItemName":"Gabapentin"},{"id":"201a6fcc-11c6-5f00-b820-7fa69ee8b95d","slug":"duloxetine","fullItemName":"Duloxetine"},{"id":"56e4231d-ab93-5963-bc8a-989240189179","slug":"capsaicin-cream","fullItemName":"Capsaicin cream"},{"id":"01a263c7-9fe1-5a29-95ec-24e56c0c1bc9","slug":"tramadol","fullItemName":"Tramadol"}]},{"id":"9ed9a9fb-0b52-50ef-8980-c1303531094d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"4fd6ab13-09e0-57f4-a265-464eeab8c835","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"3eb7f136-ffd0-5f27-b2d1-21b49247596d","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"606fc7bf-da44-5385-95f8-0139b3c57ef7","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"9fc3997f-80c3-5333-b5bd-3b3a518bdde6","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"74708745-26ce-5fd4-8c02-67ba25b5a355","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4f5855b4-c905-54ca-b02a-820f8fdd4a4a","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f09723db-fe39-5bbd-b643-d063fcd61d42","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"0d8cb386-e038-5d6f-83af-81664da82cca","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"b5a5d1dd-dd9a-59ab-8ec2-661fb3940d29","slug":"licensed-indications","fullItemName":"Licensed indications","depth":3,"htmlHeader":"<!-- begin field e3db8ec0-747e-4a7b-bb33-41269006f9b1 --><h3>Is amitriptyline licensed for neuropathic pain?</h3><!-- end field e3db8ec0-747e-4a7b-bb33-41269006f9b1 -->","summary":"","htmlStringContent":"<!-- begin item 595e2a1a-ad7d-40da-8483-eb0df7c9fe15 --><!-- begin field b83939eb-cc49-46b4-947d-14641ed33a82 --><ul><li>Amitriptyline is licensed for the treatment of neuropathic pain in adults [<a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">ABPI, 2019a</a>]. </li></ul><!-- end field b83939eb-cc49-46b4-947d-14641ed33a82 --><!-- end item 595e2a1a-ad7d-40da-8483-eb0df7c9fe15 -->","subChapters":[]},{"id":"4ab21b19-c636-56cd-b01c-d5b2ba767f2c","slug":"dose-titration","fullItemName":"Dose and titration","depth":3,"htmlHeader":"<!-- begin field 9801c246-543b-4ff1-92aa-c2493c527106 --><h3>Dose and titration</h3><!-- end field 9801c246-543b-4ff1-92aa-c2493c527106 -->","summary":"","htmlStringContent":"<!-- begin item fe5e1c2e-538a-4ee9-bbd6-66d90dd62da0 --><!-- begin field ff0c5c76-4708-4c7a-8055-4d286f946b64 --><ul><li>The initial dose is 10 to 25 mg amitriptyline a day (taken at night), gradually titrated up in 10 to 25 mg steps every 3–7 days in one to two divided doses to an effective dose or the person's maximum tolerated dose (no higher than 75 mg a day).<ul><li>If no improvement is seen with 75 mg a day, consider seeking specialist advice or switching to a different drug (see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/management/neuropathic-pain-drug-treatment/#follow-up\">Follow up</a>). </li><li>Dosages higher than 75 mg a day could be considered in consultation with a specialist pain service.</li></ul></li><li>Consider trialling amitriptyline for 6–8 weeks, with at least 2 weeks at the maximum tolerated dose, before deciding it is not effective.</li><li>If amitriptyline is not effective or not tolerated, discontinue treatment gradually over a minimum of 4 weeks to prevent discontinuation symptoms (such as dizziness, nausea, paraesthesiae, anxiety, diarrhoea, flu-like symptoms, and headaches).</li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">Dworkin, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">Taylor, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">Joint Formulary Committee, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">NICE, 2019a</a>]</p><!-- end field ff0c5c76-4708-4c7a-8055-4d286f946b64 --><!-- end item fe5e1c2e-538a-4ee9-bbd6-66d90dd62da0 -->","subChapters":[]},{"id":"4bec7e12-076d-5fa1-b6fe-dcda55c37d01","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field 34ced717-df63-4edb-b143-2619e77bd897 --><h3>Pregnancy and breastfeeding</h3><!-- end field 34ced717-df63-4edb-b143-2619e77bd897 -->","summary":"","htmlStringContent":"<!-- begin item 004c1527-2b2f-4467-a4f2-56d753df8484 --><!-- begin field 0c984da0-e50c-46b2-bea2-4312404c2801 --><h4>Pregnancy</h4><ul><li>Amitriptyline is not recommended in women who are pregnant unless the benefits outweigh the risks.<ul><li>There is no robust evidence that exposure to amitriptyline in early pregnancy causes infant congenital malformation, but a teratogenic effect cannot be ruled out.</li></ul></li></ul><h4>Breastfeeding</h4><ul><li>Amitriptyline and its metabolites are excreted in low levels in breastmilk and this is not expected to cause any adverse effects, especially if the infant is aged over 2 months of age, however, rare sedation has been reported in neonates. </li><li>However, the manufacturer advises that a decision must be made whether to discontinue breastfeeding or avoid amitriptyline.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">LactMed, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">ABPI, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">UKTIS, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field 0c984da0-e50c-46b2-bea2-4312404c2801 --><!-- end item 004c1527-2b2f-4467-a4f2-56d753df8484 -->","subChapters":[]},{"id":"af3ed6d3-4d05-5a2d-80c1-59f149bc744b","slug":"other-prescribing-issues","fullItemName":"Other prescribing issues","depth":3,"htmlHeader":"<!-- begin field 71bebf47-17ae-4fc5-98b9-51e397f57ea6 --><h3>Other prescribing issues </h3><!-- end field 71bebf47-17ae-4fc5-98b9-51e397f57ea6 -->","summary":"","htmlStringContent":"<!-- begin item 3ec8cbd3-7772-4e8d-b8a5-aff13f2d9275 --><!-- begin field 3c7c6b74-6bcd-4af8-8198-f191b4df95d2 --><ul><li>For further information on how to prescribe amitriptyline, including contraindications and cautions, adverse effects, drug interactions, and use in pregnancy and breastfeeding, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/depression/\">Depression</a>.</li></ul><!-- end field 3c7c6b74-6bcd-4af8-8198-f191b4df95d2 --><!-- end item 3ec8cbd3-7772-4e8d-b8a5-aff13f2d9275 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}